INCRETIN MIMETICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In January 2024, Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical business, launched a biosimilar of the popular anti-diabetic medicine Liraglutide for the first time in India. The medicine is being marketed under the brand name Lirafit after receiving permission from the medicine Controller General of India (DCGI).
• In August 2023, Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, announced the launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. These tablets are a therapeutic equivalent generic version of KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release) tablets that have been approved by the U.S. Food and Drug Administration.
• In November 2022, Biocon Limited, an innovation-driven global biopharmaceutical company, signed a semi-exclusive partnership agreement with Zentiva, a leading European pharmaceutical company, to commercialize Liraglutide, a vertically integrated, complex formulation for the treatment and management of Type 2 diabetes and obesity.
• In July 2021, AstraZeneca, a multinational biotechnology company, announced that its product BYDUREON BCise (exenatide extended-release), a once-weekly injectable suspension, had been approved in the U.S. by US FDA for the treatment of type 2 diabetes (T2D), to improve glycemic control in pediatric patients aged 10 to 17 years as an adjunct to diet and exercise.

*